• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Key factors for non-response to ranibizumab in macular degeneration identified

byChaz Carrier
April 13, 2014
in Chronic Disease, Ophthalmology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

Image: PD 

1. Fibrovascular pigment epithelial detachment (PED) and serous PED were associated with non-response to intravitreal ranibizumab treatment as determined by visual acuity testing. 

2. Fibrovascular PED and type 1 choroidal neovascularization were associated with non-response as determined by fundus findings. 

Evidence Rating Level: 2 (Good)            

Study Rundown: For age-related macular degeneration (AMD), intravitreous ranibizumab is an effective treatment option for many patients.  A small subset of patients however, do not respond to this treatment.  In this study, patients with AMD were reviewed to identify and characterize non-responders to intravitreal ranibizumab treatment. The authors found that several factors were associated with non-response to the anti-VEGF treatment as determined by best-corrected visual acuity (BCVA) and fundus findings. These factors include initial fibrovascular pigment epithelial detachment (PED), serous PED, and type 1 choroidal neovascularization. An important strength of this study is a large patient sample size. Limitations in this study include the retrospective study design, which makes it difficult to establish a causal relationship, as well as the large 95% confidence intervals. Nonetheless, this study suggests that ophthalmologists should be aware of these potential predictive factors when treating AMD patients with intravitreal ranibizumab.

Click to read the study in British Journal of Ophthalmology

RELATED REPORTS

No difference between pharmacologic treatments in age-related macular degeneration risk reduction

Clearside’s CLS-AX shows promise in treatment of wet age-related macular degeneration

Stereotactic radiotherapy reduces anti-VEGF injection requirements in neovascular age-related macular degeneration

Relevant Reading: Intravitreal ranibizumab for neovascular age-related macular degeneration patients with good baseline visual acuity and the predictive factors for visual outcomes

In-Depth [retrospective cohort]: This study retrospectively reviewed the clinical records of 141 eyes in 141 AMD patients. All patients received a monthly intravitreal injection of ranibizumab for 3 months followed by PRN intravitreal injections for 9 months. Non-responders to the anti-VEGF treatment were defined as patients with worsened BCVA, increased exudative fundus findings and/or an increased central retinal thickness at 12 months. Logistic regression models were created to analyze non-responders’ initial characteristics. Initial fibrovascular PED (OR=22.9, 95%CI=2.61-201) and serous PED (OR=4.12, 95%CI=1.08-15.8) were associated with non-response to ranibizumab treatment as determined by BCVA. Initial fibrovascular PED (OR=33.5, 95%CI=2.95-381) and type 1 choroidal neovascularization (OR=6.46, 95%CI=1.39-30.0) were associated with non-response as determined by fundus findings.

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: macular degenerationranibizumab
Previous Post

TGF-β1 polymorphism may protect against diabetic retinopathy

Next Post

Childhood sexual abuse associated with later suicide attempts

RelatedReports

Quick Take: Association of Visual Impairment With Economic Development Among Chinese Schoolchildren
Chronic Disease

No difference between pharmacologic treatments in age-related macular degeneration risk reduction

May 8, 2025
Antioxidants, omega-3 lack benefit in age-related macular degeneration
Pharma

Clearside’s CLS-AX shows promise in treatment of wet age-related macular degeneration

October 28, 2024
Blindness and visual impairment decreasing worldwide
Chronic Disease

Stereotactic radiotherapy reduces anti-VEGF injection requirements in neovascular age-related macular degeneration

August 8, 2024
#VisualAbstract: Low-Dose Daily Aspirin does not Affect the Progression of Age-Related Macular Degeneration
StudyGraphics

#VisualAbstract: Low-Dose Daily Aspirin does not Affect the Progression of Age-Related Macular Degeneration

June 14, 2024
Next Post
Hypercortisolemia in ICU patients is due to reduced cortisol metabolism, not increased production

Childhood sexual abuse associated with later suicide attempts

Multiple opioid prescriptions associated with higher hospital admissions

Prenatal SSRI use may increase risk of autism

TV associated with higher BMI in teens

Potential association between toddler behavior and infant media exposure

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • SGLT2 inhibitors may delay cognitive impairment in elderly patients with heart failure
  • Nerandomilast slows decline in FVC in idiopathic pulmonary fibrosis
  • Mazdutide significantly reduces weight in adults with overweight or obesity
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.